A systematic review of the cost and cost-effectiveness of standard oral nutritional supplements in the hospital setting by Elia, M. et al.
Accepted Manuscript
A systematic review of the cost and cost-effectiveness of standard oral nutritional
supplements in the hospital setting




To appear in: Clinical Nutrition
Received Date: 27 November 2014
Revised Date: 23 April 2015
Accepted Date: 16 May 2015
Please cite this article as: Elia M, Normand C, Norman K, Laviano A, A systematic review of the cost
and cost-effectiveness of standard oral nutritional supplements in the hospital setting, Clinical Nutrition
(2015), doi: 10.1016/j.clnu.2015.05.010.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all















A systematic review of the cost and cost-effectiveness of standard oral 1 
nutritional supplements in the hospital setting 2 
 3 
Elia M1, Normand C2, Norman K3 and Laviano A4 4 
 5 
1Faculty of Medicine, University of Southampton, National Institute of Health 6 
Research Biomedical Research Centre (Nutrition), Southampton and University 7 
Hospital Southampton NHS Foundation Trust, Southampton, England, UK  8 
2
 Centre for Health Policy and Management, Trinity College, Dublin, Republic of 9 
Ireland  10 
3
 Research Group on Geriatrics, Charité Universitätsmedizin, Berlin, Germany  11 
4
 Department of Clinical Medicine, Sapienza University, Rome, Italy  12 
 13 
Correspondence: M. Elia, National Institute of Health Research Biomedical Research 14 
Centre (Nutrition), University Hospital Southampton NHS Foundation Trust, 15 
Tremona Road, Southampton, SO16 6YD, England, UK 16 
Email: M.elia@soton.ac.uk 17 


















Background and aims: There is limited information about the economic impact of 3 
nutritional support despite its known clinical benefits. This systematic review 4 
examined the cost and cost-effectiveness of standard (non-disease specific) oral 5 
nutritional supplements (ONS) administered in the hospital setting only. 6 
Methods: A systematic literature search of multiple databases, data synthesis and 7 
analysis were undertaken according to recommended procedures. 8 
Results: Nine publications comprising four full text papers, two abstracts and three 9 
reports, one of which contained 11 cost analyses of controlled cohort studies, were 10 
identified. Most of these were based on retrospective analyses of randomised 11 
controlled trials designed to assess clinically relevant outcomes. The sample sizes of 12 
patients with surgical, orthopaedic and medical problems and combinations of these 13 
varied from 40 to 1.16 million. Of 14 cost analyses comparing ONS with no ONS (or 14 
routine care), 12 favoured the ONS group, and among those with quantitative data (12 15 
studies) the mean cost-saving was 12.2 %. In a meta-analysis of five abdominal 16 
surgical studies in the UK, the mean net cost saving was £772 per patient (se £346; P 17 
`= 0.026). Cost savings were typically associated with significantly improved 18 
outcomes, demonstrated through the following meta-analyses: reduced mortality (Risk 19 
ratio 0.650, P <0.05; N = 5 studies), reduced complications (by 35% of the total; 20 
P<0.001, N = 6 studies) and reduced length of hospital stay (by 2 days, P <0.05; N = 6 21 
surgical studies). Two studies also found ONS to be cost-effective, one by avoiding 22 
development of pressure ulcers and releasing hospital beds, and the other by gaining 23 















Conclusion: This review suggests that standard ONS in the hospital setting produce a 1 
cost-saving and are cost-effective. The evidence base could be further strengthened by 2 
prospective studies in which the primary outcome measures are economic. 3 
 4 
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1. Introduction 1 
 2 
     Although there is substantial information about the beneficial effects of nutritional 3 
support on clinical outcomes, such as mortality, development of conditions requiring 4 
hospital admissions and speed of recovery from illness1-6, there is much less 5 
information about its economic consequences. Several systematic reviews have been 6 
undertaken7-11  but these have often not separated the effects of different types of 7 
nutritional interventions in different settings and many analyses appear to have been 8 
missed. Furthermore, although in countries such as the UK12 and the Republic of 9 
Ireland13, it has been estimated that the cost of malnutrition exceeds 10% of the total 10 
public expenditure on health and social care, the extent to which nutritional 11 
interventions  impact on the budget and produce cost-effective outcomes is much less 12 
clear. For example, various types of nutritional interventions, and sometimes the same 13 
types of interventions in the same setting, have been reported to produce both a net 14 
cost and  net cost saving depending on the patient group and study conditions14. At 15 
least some of the variability between studies can be explained by the healthcare 16 
setting, the condition being treated, and the type of nutritional support, which may 17 
vary from a specialised form of nutritional support, such as enteral tube feeding and 18 
parenteral nutrition, to oral nutrition support, such as dietary advice to modify the 19 
texture or composition of the diet, food fortification and commercial oral nutritional 20 
supplements (ONS). The variability in outcomes involving ONS alone also depends 21 
on multiple factors, including the underlying disease, nutritional status and both the 22 
amount and type of ONS ingested. For example, general purpose, multi-nutrient ONS 23 
(standard ONS), designed for the management of a wide range of patients with 24 
disease related malnutrition contain a broad range of macronutrients and 25 















disease specific ONS for which the macro- and / or micronutrient levels have been 1 
adapted for use in specific clinical conditions.. In the hospital setting, ONS are 2 
typically used for relatively short periods of time, often in patients suffering from 3 
acute conditions (including the acute complications of elective and emergency 4 
procedures) while in the community setting, they are generally used for longer periods 5 
of time, often in patients with chronic conditions. In view of the diverse composition 6 
of ONS, the different populations for which they are prescribed, and the various 7 
clinical and economic outcomes that are influenced by care settings and transitions 8 
between care settings, this review focussed on addressing the following question: do 9 
standard ONS administered only during hospitalisation produce cost-effective 10 
outcomes and cost savings? The review also aimed to identify gaps in knowledge that 11 
need to be addressed to help guide clinical practice.  12 
 13 
2. Methods 14 
 15 
     The systematic review was planned and conducted according to published 16 
guidelines, including those provided by the Cochrane Collaboration15, the UK 17 
National Health Service Centre for Reviews and Dissemination16 (CRD, Centre for 18 
Reviews and Dissemination, 2009), and the PRISMA guidelines17. This review on the 19 
use of ONS in hospital was part of a broader literature review that included the use of 20 
ONS in the community setting which will be reported separately18. 21 
 22 
2.1. Inclusion and exclusion criteria  23 
     The inclusion and exclusion criteria of the current review were defined before the 24 
literature search was undertaken.  Both interventional and observational studies 25 















eligible. Only papers or abstracts reported in English were included. Animal studies 1 
were excluded. Studies of adults and children (>1 year of age) of any nutritional status 2 
(malnourished and well nourished) treated as hospital inpatients in any country were 3 
included, but studies in pregnant and lactating women were excluded.  4 
     Studies of ONS alone or with other types of intervention, such as dietary advice 5 
(dietary counselling) or enteral tube feeding, were eligible for inclusion, but studies 6 
that included drug interventions were excluded. For the purposes of this review, only 7 
standard ONS were included which were defined as a commercially available, ready 8 
to consume, multi-nutrient (complete or incomplete), liquid or semi-solid product 9 
providing a mixture of macronutrients and micronutrients and produced by specialist 10 
medical nutrition manufacturers. Studies of disease-specific formulae adapted to the 11 
needs of specific diseases and/or digestive or metabolic disorders19 were excluded as 12 
were immune modulating formulae. Dietary counselling was defined as dietary advice 13 
provided by a qualified healthcare worker to modify the quantity and/or proportions 14 
of food ingested. Studies of interventions with ONS, with or without other 15 
interventions, were compared with no ONS (or routine care, which may include ONS 16 
in a proportion of patients). Studies comparing ONS with another type of nutritional 17 
intervention, such as dietary advice were also eligible for inclusion. Studies that 18 
included exercise as an intervention, ONS in combination with drug therapy such as 19 
anabolic steroids, and studies of one type of ONS v. another were excluded.  20 
     The primary outcome of this review was cost or cost-effectiveness, with no 21 
restrictions on the type of effectiveness outcomes. The secondary outcome was any 22 
functional and/or clinically relevant effect pertinent to cost-effectiveness analysis. 23 
 24 















     The literature search was undertaken on 31 March 2014. OvidSP was used to 1 
search Embase (Embase Classic + Embase 1947 to 2014 week 13) and Medline (1946 2 
to 2014 March week 3). On the same date, a literature search was carried out using the 3 
Health Economic Evaluation Database (HEED) and the Cochrane Library (which 4 
includes the National Health Service Economic Evaluations Database or NHS EED, 5 
Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled 6 
Trials and Database of Abstracts of Reviews and Effects). Articles from all of these 7 
databases were exported into a single ‘library’.  The Cost Effectiveness Analysis 8 
(CEA) Registry was checked independently.  9 
     The terms shown below were used to make a broad search which included the title 10 
of publication, abstract, subject headings and any key words. They were organised 11 
into three groups: 1. economic, economics, cost, costs, finance, finances, budget, 12 
budgets, expense, expenses, price, prices, AUD, USD, EUR, GBP, dollar, dollars, 13 
euro, euros, pound and pounds 2. supplement, supplements, ONS, sip, sips, feed, 14 
feeds, nutrition and nutritional 3. utility, healthcare, resource, resources, effective, 15 
effectiveness, benefit and benefits.  16 
     The articles were exported into a database only if they included at least one search 17 
term within each of the three groups. Hand searching of the references of the retrieved 18 
final papers, and discussions with experts in the field were also carried out. Potentially 19 
eligible papers were identified by reading the titles, abstracts and key descriptor 20 
words/phrases. Full papers were obtained whenever possible according to the pre-21 
specified inclusion criteria. The studies were initially screened by an assessor after 22 
reading the title and abstract, and if the publication was deemed to be potentially 23 















discussed with another assessor. Relevant abstracts were briefly summarised and used 1 
to search potential full papers by the same authors, but they were not subjected to 2 
detailed economic assessment as they contained insufficient information. The 3 
assessment of trial eligibility was undertaken by two independent assessors and any 4 
disagreements were resolved through discussion. Figure 1 shows the reasons for 5 
excluding certain studies. Other publications were identified from prior knowledge, 6 
contact with experts in the field and hand searching of publications on ONS. One of 7 
these publications was based on the NICE costing template20, which was replicated by 8 
one  author of the current review (ME) to examine the effect of standard ONS in 9 
hospital inpatients. 10 
 11 
2.4. Quality assessment 12 
     The assessment of the quality of studies (risk of  bias) was  based on the Cochrane 13 
Handbook for Systematic Reviews of Interventions, updated in 201115 (controlled 14 
clinical trials), Strengthening the Reporting of Observational Studies in Epidemiology 15 
(STROBE)21 (observational epidemiology), and Drummond et al22  (economic studies  16 
- applied only to prospective studies with stated economic outcomes). In view of the 17 
lack of clear and unambiguous economic criteria  relevant to intervention studies with 18 
ONS, a few of the items suggested by Drummond et al22 were defined, clarified or 19 
eliminated to make them more pertinent to the current assessment (see supplementary 20 
file 1). Some publications were evaluated by more than one set of criteria. 21 
  22 
2.5. Synthesis of data and statistical analyses 23 
     Comprehensive Meta-Analysis (version 2, Biostat Inc. New Jersey, USA) was 24 















the studies included in the present review. When results were expressed in different 1 
units such as different national currencies or obtained at widely different times in 2 
different countries, the results were expressed as a proportion of the total costs or of 3 
the control group. When meta-analysis of patient level data was not possible due to 4 
lack of measures variation, the mean values from each study were analysed (study-5 
level analysis), using simple statistical tests such as t-tests and the binomial test (for a 6 
cost outcome either  favouring or not favouring the ONS group), undertaken with the 7 
Statistical Package for the Social Sciences (SPSS, version 20, Chicago USA). A P-8 
value of <0.05 (two tailed) was considered to be significant.  9 
 10 
3. Results 11 
 12 
     A total of 22,819 publications were retrieved from the literature search. No 13 
additional references were identified from the Cost Effectiveness Analysis Registry, 14 
but expert prior knowledge of the literature of relevant papers identified another five 15 
publications, which were not listed and/or not retrieved from the electronic databases 16 
(3 reports (not listed),14, 20, 23, one paper24, which was subsequently retrievable from 17 
electronic databases, and one abstract25). The original full text papers used by this 18 
review 24, 26-28, and previous systematic reviews7-11 did not use or cite the 14 economic 19 
analyses from  these five publications. Figure 1 shows that the vast majority of studies 20 
were eliminated either because they were duplicates or because the titles and abstracts 21 
clearly indicated they did not involve cost or a cost-effectiveness analysis using ONS 22 
in hospital. After closer scrutiny of the remaining studies, including examination of 23 
the full text for many of them, further studies were eliminated for the reasons shown 24 
in Figure 1, leaving only nine publications for analysis in this review14, 20, 23, 24, 26-30. 25 















analyses of controlled clinical trials26, 27, 31-39 (all of which were RCTs apart from one 1 
27), and another20 representing an update of a previous report40.  One of the excluded 2 
studies involved a multicomponent intervention in which the intake of ONS in the 3 
intervention group was less than in the control group receiving routine care41. Another 4 
study, with a historical control group42 was excluded  for  several reasons: only a 5 
minority of patients in the control and intervention groups received ONS; the control 6 
group received more ONS than the intervention group; patients in the intervention 7 
group received different types of oral interventions (some ONS and protein enriched 8 
meals and others only protein enriched meals), with no subgroup analysis. One of the 9 
12 hospital studies in the British Association for Parenteral and Enteral Nutrition 10 
(BAPEN) economic report43, was also excluded because it used a ‘home made’ feed 11 
of unknown composition, instead of a commercial feed of known composition. A 12 
further paper from the USA24 did not specify whether “complete nutritional 13 
supplement, oral” was restricted entirely to  standard ONS, but contact with one of the 14 
authors of the paper revealed that about 80% of the ONS were standard ONS. This 15 
paper was included in the review, but interpreted with caution.  16 
 17 
3.1. General features of studies 18 
     Supplementary file 2, Table 1 indicates the general study characteristics including 19 
the funding source of individual studies and in addition provides complementary 20 
information on the cost and cost-effectiveness studies to that provided below  From 9 21 
publications 14, 20, 23, 24, 26-30 fourteen cost-analyses based on interventions exclusively 22 
in the hospital setting were identified (including one which was part of  a cost-23 
effectiveness analysis28, and one in which the hospital component was established 24 















literature search 26-28  and only two were prospective26, 27. Most analyses were 1 
identified from detailed reports produced by national organisations (NICE and 2 
BAPEN). Two cost-effectiveness analyses23, 28  used economic models that 3 
incorporated data from previous publications. Most of the controlled clinical trials 4 
used in the cost analyses included a range of clinically relevant outcomes (mortality, 5 
muscle strength and post-operative complications).) which were reviewed. 6 
     Ten cost analyses were based on data collected in the UK and another four in 7 
USA24, Australia28, Belgium37 and Switzerland35 (Supplementary File 2,Table 1). The 8 
two cost-effectiveness analyses undertaken in Australia28 and England23, were based 9 
on data collected in both their own countries and other countries.  10 
     Among the eleven studies comparing ONS with no ONS, one included the cost of  11 
nursing assistance to help with ingestion of ONS 28,  another the labour and 12 
administrative expenses 24 and yet another the extra cost of implementing a 13 
management pathway involving screening, assessment and some enteral tube 14 
feeding23. Two studies compared ONS with routine care 34, 36, one of which 15 
specifically indicated that routine care included ONS (if for example it was 16 
recommended by the dietitian)36. The other study did not indicate this34 although it 17 
was known that ONS was used routinely in the hospital in which the study was 18 
undertaken. Only one study compared ONS with placebo39.  Table 1 in 19 
Supplementary File 2 summarises the comparisons. In all studies, ONS was given in 20 
addition to food. The study designs did not attempt to replace food with ONS. 21 
     Calculations of ONS costs in hospital were based on the duration and amount of 22 
the prescription, which ranged from about 5 days to 32 days and typically 300-600 23 















ONS used was not stated, but the prescription and administration costs were 1 
mentioned24, 28.  2 
     Seven studies involved malnourished subjects 20, 23, 28, 34, 35, 37, 38 identified using 3 
various criteria (Supplemetary File 2,Table 1). Seven involved malnourished and non-4 
malnourished subjects according to anthropometric criteria such as BMI26, 31-33, 36, 39, 5 
44
, and one did not report weight or nutritional status24. 6 
     The main outcome measure in all four modelling studies was either a cost20, 24 or 7 
cost-effectiveness analysis23, 28 but they relied on information obtained from 8 
previously published studies undertaken for other purposes. In two clinical studies, 9 
economic data were secondary outcome measures26, 27. These and other clinical 10 
studies reported a variety of outcome measures, such as weight, dietary intake, and 11 
functional and/or clinical outcome measures.  12 
 13 
3.2. Outcomes  14 
(a) Cost analyses: results of individual studies 15 
     Interventional studies:  The two prospective controlled trials with a cost-analysis 16 
reported a net cost saving in favour of the ONS group. In the study of Smedley et al26, 17 
which involved 89 patients undergoing abdominal surgery, the mean expenditure of 18 
the ONS group was lower than that of the control group (no ONS) by a mean of £261, 19 
with no significant differences between  groups.  Although the paper stated that the 20 
costing methodology would be reported in a subsequent publication, this was not 21 
identified. In the other original study which involved 181 patients undergoing 22 
orthopaedic surgery27,  the cost of the ONS group was  also lower than that of the 23 
control group by a median of £130.21 per patient. The length of stay costs did not take 24 















BAPEN report). No statistical tests of significance or measures of variation were 1 
reported, but the paper concluded that even moderate levels of untargeted nutritional 2 
support (prescription of 600 kcal/day) given post-operatively can be an effective part 3 
of routine orthopaedic care in terms of cost and reduction in post-operative 4 
complications.  5 
Tables 1, 2 and 3 summarise the retrospectively established mean study level results 6 
from the BAPEN report, together with some additional calculated summary results. 7 
All five abdominal surgical studies meeting the inclusion criteria of this review 8 
showed a net cost saving in favour of ONS. These averaged at £873/patient according 9 
to calculations based on bed-day costs, £431/patient according to excess bed-day 10 
costs, and £216/patient based on complication costs. The combined abdominal and 11 
orthopaedic surgical studies were associated with even more favourable results 12 
(Tables 1, 2 and 3). Among the three non-surgical studies, two favoured the ONS 13 
group. When all the hospital studies in the BAPEN report were amalgamated 14 
(surgical, non-surgical and mixed surgical and non-surgical groups) the overall net 15 
cost saving favouring the ONS group was either statistically significant (calculations 16 
based on complication costs) or close to being significant (calculations based on bed-17 
day and excess bed-day costs).  18 
In two abstracts of economic models comparing ONS with no ONS based on 19 
previously published clinical data, the cost savings favoured the ONS group. In one of 20 
these, the cost saving was £138 per malnourished patient admitted to hospital29, and in 21 
the other  £5 - £460 per elderly  patient  at high risk of developing pressure 22 
ulcers30(the range reflecting the differences in ulcer stages 1 to 4).  23 
     Observational study: The study of Philipson et al24 involved a retrospective 24 















11 year period in the USA, from which 1.2 million were selected for the cost analysis: 1 
0.6 million (1.6% of the total population) who received ONS and another 0.6 million 2 
who did not receive ONS but were matched for age, gender and the components of the 3 
Charlson comorbidity index (based on diagnostic groupings). The multivariate 4 
analysis, which was undertaken to control for confounding variables including 5 
hospital specific covariates such as the number of hospital beds and urban location, 6 
did not incorporate weight status or nutritional status. Instrumental variables analysis 7 
was undertaken to mitigate against potential selection bias associated with unknown 8 
variables. The reported length of hospital stay was 21.0% shorter in the ONS group 9 
(8.59 v10.88 days), which together with a consideration of other variables resulted in 10 
a net cost saving of $4734 (se $10.07) per episode in favour of the ONS group (21.6% 11 
cost saving).  The authors of the paper felt that the results of instrumental variables 12 
analysis, supported by some validity tests, formed an appropriate basis to adjust for 13 
unknown confounding variables. For example they considered the possibility that 14 
ONS use (the instrument) might be related to provider ‘quality’ (a ‘valid’ instrument 15 
would be expected to show no correlation).  Therefore, the authors correlated ONS 16 
use and ‘hospital quality’ as measured by the adoption of 11 new technologies such as 17 
cardiac catheterisation, thrombolysis and image guided surgery. They reported no 18 
significant relationships or inconsistent relationships, some of which were positively 19 
related and others negatively related. They also found that when comparing high and 20 
low ONS propensity hospitals, there were only small differences in co-morbidities, 21 
such as cardiovascular disease, although these were often significant due to large 22 
sample sizes.   23 
     Studies with interventional and observational components: The model used by 24 















Queensland, Australia, when appropriate nutritional support was used to prevent 1 
development of pressure ulcers.  2 
The 2012 NICE costing report also concluded that there was an overall net cost saving 3 
in favour of the proposed pathway (£71,800 per 100,000 general population of 4 
England20). The model, which  was based on an earlier one that also found a net cost 5 
saving in favour of the proposed pathway40,  was dominated by the effect of ONS in 6 
reducing length of hospital stay (the percentage reduction in costs was not reported 7 
and could not be computed from the costing template). This was more than sufficient 8 
to counteract the extra costs of screening, assessment and treatment with ONS, 9 
ultimately producing a net cost saving. 10 
(b) Cost analyses: results of amalgamated studies 11 
     Subject level analyses (based on meta-analyses of studies comparing mean ± sd 12 
between groups): Figure 2 shows the meta-analysis of the net cost saving of five UK 13 
studies, all involving abdominal gastrointestinal surgery and all based on 2003 prices. 14 
The overall summary statistic favoured the ONS group (cost saving £772/ patient (se 15 
£346), P = 0.026; I2 = 0%) (upper graph). The percentage cost saving (13.55% (se 16 
6.09%), P = 0.026; I2 = 0%) also significantly favoured the ONS group (lower graph).  17 
Study level analysis (based only on the difference in mean values between groups): 18 
Twelve studies were found to produce a net cost saving favouring the ONS group by a 19 
mean 12.2% (sd 23.8%) (P = 0.105 using the one sample t-test for the difference 20 
between groups, and P = 0.050 using the one sample Wilcoxon signed-rank test (the 21 
results tended to be skewed; Kolgomorov Smirnov test; P = 0.135)). Out of 14 studies 22 
for which it was possible to dichotomise the results into those favouring and not 23 
favouring the ONS group, 12 favoured the ONS group (P = 0.013; the binomial test). 24 















mean age of the study populations (<65 years v. ≥65 years), nutritional status 1 
(malnourished v. combination of malnourished and non-malnourished subjects), type 2 
of intervention (ONS v. no ONS and ONS v. routine care), and type of analysis 3 
(prospective v. retrospective; interventional v. observational). They universally 4 
favoured the ONS group, but the number of studies was small and the variation 5 
between them was large, with the result that the net cost saving was often not 6 
statistically significant. Furthermore, per cent cost-saving was not found to be 7 
significantly related to the  year of publication of the study (r = 0.298, P = 0.348; N = 8 
12 studies) or to the estimated average (mean or median) duration of ONS 9 
administration (r = 0.186, P = 0.563; N = 12 studies). 10 
(c) Cost-effectiveness analyses: results of individual studies  11 
      The probabilistic cost-effectiveness model of Banks et al28 suggested that use of 12 
nutritional support (mainly ONS; compared to no specific additional nutritional 13 
support) in elderly patients in hospitals in Queensland, Australia, avoids development 14 
of 2896 (sd 632) cases of pressure ulcers per year, whilst releasing 12396 (sd 4991) 15 
bed days, and producing  savings of €2,869,526 (sd €2,078,715) per year. It was not 16 
possible to accurately assess the stage of pressure ulcers, which would have 17 
influenced the costs. This study used information from a previously published meta-18 
analysis of 5 RCTs45, which showed that nutritional support prevented the 19 
development of pressure ulcers (odds ratio 0.74) in a high risk group of patients. 20 
When the data was re-analysed by one of the authors of the meta-analysis who is also 21 
an author of the present review (ME), the summary result was virtually unaffected 22 
when the single tube feeding study was excluded from the meta-analysis (odds ratio 23 
0.75) or when the single study with disease specific ONS was excluded (odds ratio 24 















     In the report commissioned by NICE40, the incremental cost per QALY gained 1 
was £6,608, which was considered to be cost-effective using the threshold of £20,000 2 
per QALY gained. A large number of one-way sensitivity analyses confirmed the 3 
cost-effectiveness when the new pathway incorporating the NICE guidelines on 4 
nutritional care was compared to the current pathway of care. A possible exception 5 
concerned a scenario where the reduction in mortality attributable to ONS was small 6 
(or the relative risk high; the meta-analysis from the systematic review showed the 7 
relative risk to be 0.84 (95% CI 0.68, 1.03)) and the duration of intervention long and 8 
without increased health gains.  A two-way sensitivity analysis showed that both an 9 
increase in prevalence of malnutrition and mortality amplified the cost-effectiveness. 10 
With a prevalence of malnutrition of >8% and a mortality of about 4%, which was 11 
considered to apply to the inpatient population, the incremental cost-effectiveness 12 
ratio was <£6,000 per QALY gained. Furthermore, if enteral tube feeding was 13 
excluded from the model to restrict the nutritional support to ONS, the new pathway 14 
would be expected to become more cost-effective, albeit to a small extent given that 15 
in the model, enteral tube feeding contributed little to the overall costs and apparently 16 
not at all to the additional QALYs gained. The report also indicated that the proposed 17 
pathway involving screening, using ‘MUST’ and use of ONS was also cost-effective 18 
compared to one involving clinical screening by nurses followed by ONS (base case 19 
analysis for incremental cost-effectiveness ratio was £4,339 per QALY gained).  20 
     Other studies without quantitative relationships between costs and effectiveness 21 
(outcome) measures have been considered in the cost-analysis section above. 22 
















d) Cost-effectiveness analyses: a consideration of clinically relevant outcomes from 1 
individual and amalgamated studies 2 
     Mortality: There were no deaths in most studies involving elective surgical 3 
admissions, although in one of them there were three deaths out of a sample of 53 4 
patients33, and in another, two deaths before study day one, out of a sample of 100 5 
subjects32. Mortality was greater among patients admitted acutely, who were also 6 
generally older35, 36, 38. In a study with a factorial design, no mortality statistics were 7 
reported in the subgroup analysis of ONS alone v placebo alone39, although in the 8 
study as a whole there were 12 deaths out of 275 in the group that had ONS with or 9 
without additional vitamins and 14 deaths out of 274 in the group that received 10 
placebo with or without vitamins. In another study37 , the two deaths in each group 11 
were reported at the end of the investigation period which included two months 12 
supplementation in the community. Further analyses were restricted to studies in 13 
which the effects of ONS administration in the hospital setting alone could be 14 
evaluated.  A meta-analysis of studies reporting at least one death32, 33, 35, 36, 38, 39 15 
(studies with no deaths are ignored by meta-analyses of mortality), including the one 16 
in which deaths occurred before study day one32 and two others with mortality 17 
statistics at three months36 or six months35 after admission, found fewer deaths in the 18 
group that received ONS in hospital  (risk  ratio, 0.691 (95% CI, 0.483, 089); P = 19 
0.043; I2 = 0%; N = 6 studies).  Without the study of Vlaming et al39, which included 20 
vitamin supplementation in some of the subjects, the summary statistics changed little 21 
(risk ratio 0.650 (95% CI, 0.432, 0.976); P = 0.038; I2 = 0%; N = 5 studies) (Figure 3). 22 
 23 
     Complications: Out of the seven surgical studies with cost-analyses (all favouring 24 















significant differences between groups in minor or major complications or both (one 1 
of them included mortality among the complications35). A meta-analysis (random 2 
effects model) of complications in the ONS group (after adjustment for sample size 3 
differences between the ONS and control groups) found that the proportion of total 4 
complications was 35.3% (se 7.6%) less in the ONS than control group; I2 = 0% 5 
(Figure 4). 6 
     Length of hospital stay: The mean length of hospital stay in all surgical studies 7 
favoured the ONS group26, 27, 31-35 but one of the five UK studies did not report 8 
measures of variability between subjects33. Therefore, the meta-analysis of the five 9 
UK studies was subjected to a sensitivity analysis in which the highest and lowest 10 
standard deviations obtained from other UK studies were assigned to this study28. 11 
Both meta-analyses favoured the ONS group by 2.07 days (P = 0.035) and 2.25 days 12 
(P= 0.013) respectively (I2= 0% for both meta-analyses). Among the other six hospital 13 
studies for which cost-analyses were available, four reported median length of stay. 14 
Overall, 10 out of the 12 studies had a mean or median length of stay that was shorter 15 
in the ONS group (P = 0.039, binomial test). 16 
     Other outcomes: Two studies reported fatigue scores, one in which there was no 17 
significant change in the ONS group and a significant deterioration in the no ONS 18 
group 32, and the other in which there was no significant difference between groups26. 19 
Among four studies that measured grip strength, one reported significantly higher 20 
strength in the ONS than the control (no ONS) group at the time of discharge31, 21 
another a significant deterioration only in the control group at the time of discharge32, 22 
and a further two studies no significant difference between groups during hospital 23 
stay27, 34. One study of elective hospital admissions measured well-being32 and another 24 















studies involving emergency admissions, two reported no significant differences 1 
between groups in discharge destination 36, 37 and the other did not report discharge 2 
destination (or functional outcomes)39.  3 
     Some studies reported significantly less weight loss in the ONS than the control 4 
group32, 34, others reported a significant weight loss in the no ONS (or routine care 5 
group) but not in the ONS group,  and yet others no significant differences between 6 
groups27, 33, 36-38. Two studies did not report changes in weight35, 39 and in one, the 7 
weight changes were reported only after discharge from hospital when ONS was still 8 
being used 37. 9 
 10 
4. Assessment of risk of bias 11 
 12 
The overall quality of the studies with respect to the combined clinical and economic 13 
outcomes, were judged to have at least a moderate risk of bias, with substantial 14 
variation between studies (for details see Supplementary file 1)  15 
 16 
5. Discussion  17 
 18 
     This review, mainly of RCTs in which national reference costs were assigned to 19 
specific conditions and interventions, suggest that the use of ONS compared to ‘no 20 
ONS’ or routine care can produce significant net cost savings. Study level analyses 21 
showed a significant overall cost saving, and a series of subgroup analyses according 22 
to malnutrition, age group, type of study and study design (Table 3) universally 23 
favoured the ONS group, although only some of these cost savings were signficant., 24 
The cost savings were generally found to be associated with a range of favourable 25 















(more QALY), and reduced length of hospital stay (earlier return to the  familiar home 1 
environment). These findings are consistent with other reviews on the use of ONS in 2 
clinical practice3, 4, 6. Economic models involving interventions with ONS e.g. that 3 
used by Banks et al 28 showing a cost-effective reduction in the risk of developing 4 
pressure ulcers (consistent with data reported previously30), and the NICE model 5 
showing that ONS were cost effective improvement in QALY’s gained, made some 6 
assumptions (see Methods), but their conclusions were strengthened by the use of a 7 
probabilistic model28 or a series of sensitivity analyses respectively40. 8 
     The favourable cost and cost-effectiveness outcomes associated with the use of  9 
ONS in the hospital setting could have been predicted , partly because other studies 10 
have suggested that ONS have a range of favourable clinical effects3, 4, 6, and partly 11 
because the cost of ONS is small compared to total hospital costs. , However, it is 12 
probably more insightful and more useful for health planning and policy making to 13 
consider these issues using a single management model that extends between settings, 14 
rather than separately within individual care setting.  For example, in the NICE cost-15 
effectiveness analysis use of ONS in hospital kept more patients alive, which required 16 
additional costs to care for their extended lifespan outside hospital.. Conversely, use 17 
of ONS in the community can reduce hospitalisation46. Furthermore, ONS prices can 18 
differ between care settings,  which means there is a need to consider the whole health 19 
and social care economy rather than one setting is isolation.  20 
     The notable lack of primary cost-analyses in adults and the total absence of 21 
identifiable studies in children from the literature search weaken the generalizability 22 
of the findings, although one retrospective analysis based on observational data  in 23 
children has been published after our literature search47, which suggests that ONS 24 















     Our review included only two controlled trials that prospectively reported a cost-1 
analysis 26, 27, and in neither of them was cost or cost-effectiveness the primary 2 
outcome variable.  The only observational study reporting a retrospective cost-3 
analysis exclusively in the hospital setting found a highly significant cost saving 4 
favouring the ONS group (21.6% or $3694  per episode)24, but since disease-specific 5 
feeds were used in about a fifth of patients care should be exercised in attributing all 6 
the reported benefits to standard ONS. Extrapolation of the findings to the entire 7 
population of malnourished people admitted to hospital should also be made with 8 
caution since ONS were given to only 1.6% of patients admitted to hospital (the 9 
prevalence of malnutrition is expected to be more than an order of magnitude higher), 10 
whose nutritional status was not reported. This study aimed to control for both known 11 
and unknown variables from the observational data using instrumental variables 12 
analysis, but despite ‘validity checks’, it is not possible to definitively prove that bias 13 
due to unknown variables has been totally eliminated. Some analysts have suggested 14 
that in some circumstances misleading results may be produced by instrumental 15 
variables analysis 48-50. There is generally less concern about this type of bias with 16 
RCTs because the randomisation aims to distribute both known and unknown 17 
variables equally between the study groups. However, whilst RCTs have greater 18 
internal validity, they have less external validity than observational studies (more 19 
representative and larger samples, e.g. 1.2 million in the study by Philipson et  al)24. 20 
Both types of studies have merits and help to build a more complete picture. 21 
     The majority of studies compared ONS with no ONS under controlled conditions,  22 
which means that the results may not be directly extrapolated to routine practice 23 
where ONS is already given to a proportion of patients under less well controlled 24 















increased awareness about the importance of nutrition in clinical practice to help 1 
reduce the burden of untreated malnutrition. 2 
     It is clear from this review that much primary research needs to be undertaken to 3 
establish a more robust quantitative evidence base from studies primarily designed to 4 
examine the cost and cost-effectiveness of standard ONS in various groups of 5 
patients. This is because the quality of the reviewed studies was judged to be variable 6 
with at least a moderate overall risk of potential bias. Most of the studies were not 7 
primarily designed to assess economic outcomes, most were analysed retrospectively, 8 
and the results of the modeling studies that aimed to assess cost or cost-effectiveness 9 
as the primary outcome variable relied on data obtained by studies designed to assess 10 
non-economic outcomes. Most of the reviewed studies were funded by industry 11 
(Supplementary File 2, Table 1) raising the potential risk of publication bias, i.e. 12 
the,selective reporting of studies with favourable outcomes. However, potential 13 
publication bias also exists with government funded projects51.  Recently a call has 14 
been made to register and publish the results of all trials, to improve on the 40-50% 15 
publication rate observed between 1999 and 2007, which applies equally to industry 16 
and government funded trials 51.  Although this review has focussed on standard ONS 17 
produced commercially, which are reimbursed to a variable extent across markets, 18 
there is also a need to review other forms of nutritional support, such as snacks, food 19 
fortification, dietary advice (for which the clinical and economic evidence base 20 
appears to be weak) and tube feeding, and to examine their relative cost and cost-21 
effectiveness. The cost and cost-effectiveness of disease-specific ONS requires a 22 
separate review. 23 
     Given the variable nutritional status of patients included in different clinical trials 24 















would be valuable to establish the relative benefits of the use of ONS in patients with 1 
a low body mass index, those with unintentional weight loss ( which may occur in 2 
underweight as well as overweight or obese individuals), and those with major 3 
reductions in recent nutritional intake during key phases of their illness.  4 
     Despite variations in study design and quality (risk of bias), this comprehensive 5 
systematic review found that use of ONS produced a consistent cost saving and cost-6 
effectiveness. The extent to which this can be translated into routine clinical practice 7 
depends on the degree to which a healthcare system is competent to take advantage of 8 
these findings. Such competency varies between healthcare systems, which prioritise 9 
nutritional support to a variable extent, and which operate different incentivisation 10 
schemes, including those reward high quality practice and/or penalise poor practice. 11 
Furthermore, since many of the results of this review were dominated by studies 12 
undertaken in the UK over more than two decades, some caution should be taken in 13 
extrapolating them to a wide range of other countries using different healthcare 14 
systems and national tariffs.  15 
     Finally, this work highlights two important methodological issues. First only a 16 
minority of the economic analyses were identified from by the search engines, the 17 
majority being pinpointed by specialists in clinical nutrition (see Results section) who 18 
identified relevant information in detailed reports produced by national organisations. 19 
When an evidence base is gathered by people who are familiar with systematic review 20 
methodology but not the specific topic of the review, there is a risk that important 21 
information will be missed. Second, the criteria for assessing the quality of RCTs are 22 
not necessarily the best ones for assessing economic studies and vice versa, which is 23 
why in this review both types of assessments were done.  Furthermore, since 24 















specifically developed for nutrition, studies  the checklist by Drummond et al was 1 
carefully considered and certain items defined in order to make them more relevant 2 
and specific to nutrition studies under consideration.  3 
 4 
6. Conclusion 5 
 6 
This review suggests that use of standard ONS in the hospital setting generally 7 
produce cost savings and are cost-effective in patient groups with variable age, 8 
nutritional status and underlying conditions. More high quality prospective studies 9 
with adequate power to examine economic outcomes are needed to substantiate the 10 
findings of this review in countries with different healthcare economies.  11 
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Table 1 27 
 Net cost saving (£ per patient) due to administration of oral nutritional supplements in individual surgical, non-surgical and mixed 28 
(surgical + non-surgical) studies (based on the BAPEN report 2003 prices)14 29 


















 Average   
 
(£) 











Beattie et al34 (Scotland) 101 830.6 638.5 977.7  406.7  227.0 153.3 258.7 
Keele et al32 (England) 86 896.7 729.8 1047.2  450.2  325.6 221.5 386.5 
 Rana et al31 (England) 40 1249.4 1001.9 1478.7  612.8  596.5 387.8 752.2 
 MacFie et al33 (England) 52 1125.8 950.0 1307.6  557.6  -161.6 -111.2 -183.2 
 Smedley et al26 (England) 89 260.7 213.3 304.8  130.1  92.9 74.0 118.6 
            
Surgical: 
Orthopaedic 





































 Average   
 
(£) 









 Lawson et al27 (England) 181 444.9 381.0 512.6  181.0  483.3 333.7 593.8 
            
Non-surgical Potter et al36 (Scotland) 381 330.4 262.4 398.4  270.4     
 Gazzotti et al37 (Belgium) 80 -246.4 -198.8 -294.0  -204.4     
 Gariballa et al38 (England) 40 2090.8 1715.3 2498.6  2527.2  116.2 95.4 130.3 
            
Mixed: Vlaming et al39 (England) 281 -1306.3 -1046.3 -1566.3  -942.3     
a N = number of subjects in intervention (ONS) and control groups 30 
bBed-day and excess bed-day costs are based on length of hospital stay. Excess bed-days are associated with prolonged length of stay (above the Healthcare 31 
Resource Group Trim point), and they are usually associated with lower costs since they mostly involve basic care and hotel costs. Complication costs are based 32 















groups of patients according to the type of admission, type of treatment received and the type and number of complications. The authors of the primary studies 34 
were contacted to clarify uncertainties. 35 
Table 2 36 
Summary of net cost saving (£ per patient) due to administration of oral nutritional supplements in surgical, non-surgical and mixed 37 
(surgical + non-surgical) groups of studies (based on the BAPEN report 2003 prices)14 38 
Studies 
 








 Average  Lower Quartile  
Upper 
Quartile 













































 P valueb 0.007 0.008 0.007  0.007  0.118 0.110 0.119 
Surgical: Average 
95% CI (£) 
1328.5 
-1.4, 2658.3 
      1100.9 





































 Average  Lower Quartile  
Upper 
Quartile 






























 P valueb 0.064 0.065 0.065  0.094  0.029 0.033 0.028 
All studies Average 

















































 See footnote to Table 1 39 
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Table 3 42 
Post hoc cost analyses of hospital studies comparing ONS with no ONS or routine carea 43 
Study Country N Nutritional  
status 
Age group Type 
of 
study  
Comparison Cost saving per 
subject in favour 




BAPEN report 200514         
(i) Rana et al 199231 UK 40 M + NM <65 years I ONS v no ONS £1249.4 20.71 
(ii) Keele et al 199732 UK 86 M + NM <65 years I ONS v no ONS £896.7 18.1 
(iii) Smedley et al 200426b UK 89 M + NM <65 years I ONS v no ONS £260.7 4.93 
(iv) MacFie et al 200033 UK 62 M + NM <65 years I ONS v no ONS £1125.8 23.04 
(v) Beattie et al 200034 UK 101 M <65 years I ONS v routine care £830.6 10.59 
(vi) Delmi et al 199035 CH 59 M ≥65 years I ONS v no ONS £4491.2 39.94 
(vii) Lawson et al 200327b UK 181 M + NM ≥65 years I ONS v no ONS £444.9 9.92 
(viii) Potter et al 200136b UK 381 M + NM ≥65 years I ONS v routine care £330.4 10.8 
(ix) Gazzotti et al 200337 BE 60 M ≥65 years I ONS v no ONS -£246.4 -7.32 
(x) Gariballa et al 199838 UK 40 M ≥65 years I ONS v no ONS £2090.8 42.73 
(xi) Vlaming et al 200139 UK 281 M  ≥65 years I ONS v no ONS -£1306.3 -49.29 
Banks et al 201328 AU 1356c Md ≥65 years I + O ONS v no ONS €143.6 (£93.25)e  















NICE 201220 UK 1410440c M  I + O ONS v no ONS g  
UK = United Kingdom; CH = Switzerland; BE = Belgium; AU = Australia; US = United States; M = malnourished; NM = non-malnourished; I = interventional 44 
study; O = observational study 45 
a
 Calculations of costs were based on bed-day costs  46 
b
 The data in the BAPEN report were used in preference to those reported in the original papers for consistency in calculations based on bed-day costs. In the 47 
BAPEN report the costs of specific surgical procedures were taken into account in estimating bed-day costs but the original papers the calculations did not 48 
involve the surgical procedure. For example, in the original paper by Smedley et al26 a cost saving of  £271 per patient translates to 11.91% of the cost of the no 49 
ONS group, while in the BAPEN report a cost saving of £292 per patient translates to only 4.93% of the cost of the no ONS group. 50 
c
 These figures which are incorporated into economic models are not based on clinical studies. In the study of Banks et al28  the number represents the point 51 
prevalence of malnourished subjects in relevant hospitals in Queensland and in NICE 201220 the number of relevant hospital admissions in one year. For the 52 
NICE model, see also f. 53 
d
 Considered to be malnourished by Banks et al, although some the patients in a meta-analysis that was used in the model were not by anthropometric criteria. 54 
e
 Based on the average currency exchange rate for the years in which the costs were calculated by the studies. The cost per patient was calculated using data 55 
provided in the paper. 56 
g
 Although there is clear net cost saving associated with the use of ONS, the exact amount depends on calculation procedures, which in turn depend on the 57 
proportion of patients assessed by a dietitian and the proportion given ONS by the dietitian and independently of the dietitian (calculations undertaken by one of 58 
















Table 4 61 
Cost saving (study level analysis) in favour of the ONS group by age, nutritional status 62 
and study designa,b 63 
 % cost-saving (continuous data)  Cost saving (binary data)
 N 
studies 




< 65 years 5e 15.5 ± 7.5 0.010  5/5f 0.063
≥65 years 7g 9.8 ± 31.4 0.442  6/8h 0.310
      
Malnourished 64i 7.3  ± 37.9 0.688  5/7j 0.453
Malnourished + non malnourished 57k    14.6 ± 7.1 0.004  6/6l 0.031
      
ONS v no ONS 10m 12.4 ± 26.3 0.169  10/12n 0.039
ONS v routine care 2o 10.7 ± 0.149 0.006  2/2p 0.500
      
Interventional studies 11q 11.3 ± 24.8 0.162  9/11r 0.065
Observational ± interventional studies 1s 21.6   3/3t 0.250
a
 Based on data presented in Table 3 64 
b None of the comparisons between subgroup categories was significant (Student’s t-test for continuous data 65 
and Fisher’s Exact test for binary (dichotomous) data) 66 
c One sample t-test (against a test value of zero) 67 
d
 Binomial test (against test proportion of 0.5 (favouring or not favouring ONS group) 68 
e-t
 references e 26, 31-34, f  26, 31-34, g 24, 27, 35-39, h 24, 27, 28, 35-39, i 34, 35, 37, 38, j 28, 34, 35, 37, 38, 40, k26, 27, 31-33, 36, 39, 52, l 26, 27, 31-
33, 36, 39, 52


















Figure 1. Flow diagram of publications included and excluded in the review 72 
  73 
Included: N = 50 
1st pass exclusion: 
N = 16,553 
2nd pass exclusion:  
Reasons for exclusions 
(N=41) 
• 25 no ONS/no ONS costs 
• 8 review articles with no   
additional relevant studies 
identified 
• 3 disease-specific feeds 
(immunonutrition) 
• 1 ongoing or proposed 
study 
• 2 not standard ONS 
• 1 not intervention 





N = 6,221 
Database searches  
Potential studies 
N = 22,819 
 
Included:  




N = 5  
Included:  
9 publications:  
• 4 full text papers (1 RCT, 1 cohort 
controlled trial, 1 observational, 1 
based on observational + RCT data);  
• 2 abstracts;  
• 3 reports (1 with 11 cost analyses, 10 
of which were RCTs, and 1 cohort 
controlled study; and 2 based on 

















Figure 2. Meta-analysis of net cost saving of five randomised controlled trials of 75 
abdominal surgery in the UK (N=358) Upper graph  Results are presented in GBP (£) 76 
(2003 prices) (mean cost saving £772/ patient (se £346), P = 0.026; I2 = 0%) Lower graph 77 
Results presented as percent reduction of control group (mean cost saving 13.5% (se 78 
6.1%), P = 0.026; I2 = 0%). Negative signs indicate cost saving * based on retrospective 79 


















Figure 3. Random effects meta-analysis of mortality reported in hospital studies with 84 
economic outcomes (Risk ratio 0.650 (95% CI 0.432, 0.976), P = 0.038; I2 = 0%, P = 85 

















Figure 4. Random effects meta-analysis of complications in surgical patients expressed 89 
as percentage of total complications. A negative sign indicates fewer complications in the 90 
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Supplementary file 1 (Assessment of risk of bias)  1 
 2 
     Table 1 shows a summary of the assessment for the risk of bias of 10 RCTs and one 3 
controlled cohort study, using criteria based on the Cochrane Handbook for Systematic 4 
Reviews of Interventions, updated in 20111. The method of randomisation was not stated 5 
in four studies2-5 and  all studies apart from one6 were not blinded. Withdrawal rates were 6 
generally small but they ranged from 0-26%. None of the studies with dropouts 7 
undertook an intention to treat analysis according to the originally designated groups. 8 
Baseline imbalances between groups were significant in some studies5, 7, 8, of borderline 9 
significance in another study9 and not reported in another study6. Statistical adjustment 10 
for the imbalances does not appear to have been carried out. Sample size calculations 11 
were not reported, even for the primary outcome variable (with the possible exception of 12 
MacFie et al3, who undertook sample size calculations on weight change, which was one 13 
of numerous outcome variables).  14 
     A few deficiencies were identified in the economic evaluations of full text papers or 15 
reports with economic data as primary (post hoc analysis) or secondary outcome 16 
measurers (a priori analysis) using criteria adapted from Drummond et al 200510 17 
(Table 2),.  In addition, in studies involving economic modelling11-14 a series of 18 
assumptions were made, including those associated with extrapolations to other 19 
populations (see Results section for a description of individual studies and the Discussion 20 
section for a consideration of the limitations). In an attempt to address specific 21 
uncertainties, NICE undertook a variety of sensitivity analyses13, 14,  Banks et al12 used a 22 















instrumental variables analysis to control for confounding variables. Any disagreements 1 
between the two evaluators were eliminated by modifying or eliminating certain 2 
questions that could be interpreted in different ways. For example, the question about 3 
whether all viewpoints had been taken into account (Table 2, item 4 (ii)), was eliminated 4 
because it is possible to have a very large number of different viewpoints. The questions 5 
about establishing a summary through a systematic overview of clinical studies was only 6 
considered relevant for systematic reviews (item 3(ii)) and the discounting was 7 
considered relevant only in studies of longer than 1 year (item 7(ii)). 8 
     Using the STROBE criteria for observational investigations, the study of Philipson et 9 
al11 was judged to be of good quality. The NICE reports on cost14 and cost-10 
effectiveness13, which included observational components, were also judged to be of 11 
good quality. Like other models, the assumptions used and the extrapolations made 12 
influence the results and the quality of the conclusions. Sensitivity analyses were 13 
undertaken to examine many of the assumptions. 14 
     Since quality of the same study may be assessed very differently according to the type 15 
of criteria used (e.g. criteria for RCTs or observational studies on the one hand and 16 
criteria for economic data on the other) this systematic review attempted to summarise 17 
the risk of bias associated with specific items, both for individual and groups of studies so 18 
that an overall judgement of their quality could be made. Given the retrospective nature 19 
of most of the cost-analyses which were based on studies intended for other purposes, the 20 
overall potential risk of bias was considered to be at least moderate, especially if lack of 21 
blinding is taken into account. However, for practical reasons, it may be difficult to 22 
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N/A = not applicable 1 
a
 Excludes deaths except when otherwise indicated.  2 
b
 Intention-to-treat defined according to CONSORT 2010 (A strategy for analyzing data in which all participants are included in the group to which they were 3 
assigned, whether or not they completed the intervention given to the group) [http://www.consort-statement.org/resources/glossary/e---l/intention-to-treat-4 
analysis/ Accessed March 2014]. 5 
c
 In studies in which baseline imbalance was found, no statistical adjustments were made 6 
d
 Cost data were established prospectively. In the other studies costs were established retrospectively on the basis of a secondary analysis of clinical data. All 7 















Table 2.  















1. Was a well-defined 
question posed in 
answerable form? 
√ √  √ √ √  
2.a Was a 
comprehensive 
description of the 
competing alternatives 
given? (that is, can you 
tell who did what to 
whom, where, and how 
often?) 
√ √  √  √  √   
3.b Was the 
effectiveness of the 
programmes or services 
established and 





















4.c Were all the 
important and relevant 
costs and consequences 
for each alternative 
identified?** 
√ √  √ √ √   




units (for example, 
hours of nursing time, 
number of physician 
visits, lost work-days, 
gained life-years)? 
√ √  √ √ √ 2/3 
(ii-iii) 
 
6. Were costs and 
consequences valued 
credibly? 
√ √  √  √ 2/4 
(ih;iv) 
 
7.d  Were costs and 
consequences adjusted 
for differential timing? 
N/A N/A  √ √ N/A  
8.  Was an incremental 
analysis of costs and 















N/A = not applicable. 
√ This character is used to indicate appropriate practice (rather than ‘yes’ or ‘no’ each of which can be the 
appropriate answer to specific questions). The Roman numerals indicate the question that was considered to 
be adequately fulfilled. What about the Arabic numbers, 1/3? 
a,b,c,d,e,f
 See below under individual questions 
g Based on information obtained from three papers 
h
 Yes, but based on LOS costs of unknown origin. 
i




9.e Was allowance 
made for uncertainty in 
the estimates of costs 
and consequences? 
√ √ 2/3 (i 
N/A) 
 √ √ √  
10.f Did the 
presentation and 
discussion of study 
results include all 
issues of concern to 
users? 

















1. (i) Did the study examine both costs and effects of the service(s) or programme(s)? (ii) Did the 
study involve a comparison of alternatives? (iii) Was a viewpoint for the analysis stated and was 
the study placed in any particular decision-making context? 
2. (i) Were any relevant alternatives omitted? [aThis question was omitted from the evaluation 
because it is almost always possible to omit a relevant alternative e.g. composition and texture of 
ONS] (ii) Was (should) a do-nothing alternative (be) considered? 
3. (i) Was this done through a randomised, controlled clinical trial?  If so, did the trial protocol 
reflect what would happen in regular practice? (ii) Were effectiveness data collected and 
summarised through a systematic overview of clinical studies? [bThis question was omitted 
because formal systematic reviews are not generally included in primary reports of clinical 
studies] If so, were the search strategy and rules for inclusion or exclusion outlined? (iii) Were 
observational data or assumptions used to establish effectiveness?  If so, what are the potential 
biases in results? 
4. (i) Was the range wide enough for the research question at hand? [cQuestion (i) was evaluated but 
the next two were not because they were considered ambiguous or irrelevant] (ii) Did it cover all 
relevant viewpoints? (Possible viewpoints include the community or social viewpoint, and those 
of patients and third-party payers.  Other viewpoints may also be relevant depending upon the 
particular analysis). (iii) Were capital costs, as well as operating costs, included?  
5. (i) Were the sources of resource utilisation described and justified? (ii) Were any of the identified 
items omitted from measurement?  If so, does this mean that they carried no weight in the 
subsequent analysis? (iii) Were there any special circumstances (for example, joint use of 
resources) that made measurement difficult?  Were these circumstances handled appropriately? 
6. (i) Were the sources of all values clearly identified?  (Possible sources include market values, 
patient or client preferences and views, policy-makers’ views and health professionals’ 















depleted? (iii) Where market values were absent (for example, volunteer labour), or market values 
did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments 
made to approximate market values? (iv) Was the valuation of consequences appropriate for the 
question posed (that is, has the appropriate type or types of analysis – cost-effectiveness, cost-
utility, cost-benefit – been selected)? 
7. (i) Were costs and consequences that occur in the future ‘discounted’ to their present values? 
[dDiscounting was considered necessary only for studies with a duration of longer than one year] 
7(ii) Was any justification given for the discount rate used? 
8. (i) Were the additional (incremental) costs generated by one alternative over another compared to 
the additional effects, benefits, or utilities generated?  
9. (i) If patient-level data on costs or consequences were available, were appropriate statistical 
analyses performed? (ii) If a sensitivity analysis was employed, was justification provided for the 
ranges of distributions of values (for key study parameters), and the form of sensitivity analysis 
used? [e A comparison of results obtained with intention to treat analysis and per protocol analysis 
was considered to be a type of sensitivity analysis, especially when the number of subjects in the 
‘per protocol’ or ‘as completed’ analysis was substantially reduced] (iii) Were the conclusions of 
the study sensitive to the uncertainty in the results, as quantified by the statistical and/or sensitivity 
analysis? [This question is not addressed by this table, but it is considered in the text] 
10. (i) Were the conclusions of the analysis based on some overall index or ratio of costs to 
consequences (for example, cost-effectiveness ratio)?  If so, was the index interpreted intelligently 
or in a mechanistic fashion? (ii) Were the results compared with those of others who have 
investigated the same question?  If so, were allowances made for potential differences in study 
methodology? (iii) Did the study discuss the generalisation of the results to other settings and 
patient/client groups? [f Any discussion relevant to alternative care settings and/or patient/client 
groups was considered to satisfy this criterion].  (iv) Did the study allude to, or take account of, 















costs and consequences, or relevant ethical issues)? (v) Did the study discuss issues of 
implementation, such as the feasibility of adopting the ‘preferred’ programme given existing 
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     Table 1 shows a summary of the assessment for the risk of bias of 10 RCTs and one 3 
controlled cohort study, using criteria based on the Cochrane Handbook for Systematic 4 
Reviews of Interventions, updated in 20111. The method of randomisation was not stated 5 
in four studies2-5 and  all studies apart from one6 were not blinded. Withdrawal rates were 6 
generally small but they ranged from 0-26%. None of the studies with dropouts 7 
undertook an intention to treat analysis according to the originally designated groups. 8 
Baseline imbalances between groups were significant in some studies5, 7, 8, of borderline 9 
significance in another study9 and not reported in another study6. Statistical adjustment 10 
for the imbalances does not appear to have been carried out. Sample size calculations 11 
were not reported, even for the primary outcome variable (with the possible exception of 12 
MacFie et al3, who undertook sample size calculations on weight change, which was one 13 
of numerous outcome variables).  14 
     A few deficiencies were identified in the economic evaluations of full text papers or 15 
reports with economic data as primary (post hoc analysis) or secondary outcome 16 
measurers (a priori analysis) using criteria adapted from Drummond et al 200510 17 
(Table 2),.  In addition, in studies involving economic modelling11-14 a series of 18 
assumptions were made, including those associated with extrapolations to other 19 
populations (see Results section for a description of individual studies and the Discussion 20 
section for a consideration of the limitations). In an attempt to address specific 21 
uncertainties, NICE undertook a variety of sensitivity analyses13, 14,  Banks et al12 used a 22 















instrumental variables analysis to control for confounding variables. Any disagreements 1 
between the two evaluators were eliminated by modifying or eliminating certain 2 
questions that could be interpreted in different ways. For example, the question about 3 
whether all viewpoints had been taken into account (Table 2, item 4 (ii)), was eliminated 4 
because it is possible to have a very large number of different viewpoints. The questions 5 
about establishing a summary through a systematic overview of clinical studies was only 6 
considered relevant for systematic reviews (item 3(ii)) and the discounting was 7 
considered relevant only in studies of longer than 1 year (item 7(ii)). 8 
     Using the STROBE criteria for observational investigations, the study of Philipson et 9 
al11 was judged to be of good quality. The NICE reports on cost14 and cost-10 
effectiveness13, which included observational components, were also judged to be of 11 
good quality. Like other models, the assumptions used and the extrapolations made 12 
influence the results and the quality of the conclusions. Sensitivity analyses were 13 
undertaken to examine many of the assumptions. 14 
     Since quality of the same study may be assessed very differently according to the type 15 
of criteria used (e.g. criteria for RCTs or observational studies on the one hand and 16 
criteria for economic data on the other) this systematic review attempted to summarise 17 
the risk of bias associated with specific items, both for individual and groups of studies so 18 
that an overall judgement of their quality could be made. Given the retrospective nature 19 
of most of the cost-analyses which were based on studies intended for other purposes, the 20 
overall potential risk of bias was considered to be at least moderate, especially if lack of 21 
blinding is taken into account. However, for practical reasons, it may be difficult to 22 
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N/A = not applicable 1 
a
 Excludes deaths except when otherwise indicated.  2 
b
 Intention-to-treat defined according to CONSORT 2010 (A strategy for analyzing data in which all participants are included in the group to which they were 3 
assigned, whether or not they completed the intervention given to the group) [http://www.consort-statement.org/resources/glossary/e---l/intention-to-treat-4 
analysis/ Accessed March 2014]. 5 
c
 In studies in which baseline imbalance was found, no statistical adjustments were made 6 
d
 Cost data were established prospectively. In the other studies costs were established retrospectively on the basis of a secondary analysis of clinical data. All 7 
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1. Was a well-defined 
question posed in answerable 
form? 
√ √  √ √ √ 
2.a Was a comprehensive 
description of the competing 
alternatives given? (that is, 
can you tell who did what to 
whom, where, and how 
often?) 
√ √  √  √  √  
3.b Was the effectiveness of 
the programmes or services 
established and consequences 
for each alternative 
identified? 
√1/3 b (iii) √b  √ b √ b √ 1/3 b 
(iii) 
4.c Were all the important and 
relevant costs and 
consequences for each 
















5. Were costs and 
consequences measured 
accurately in appropriate 
physical units (for example, 
hours of nursing time, 
number of physician visits, 
lost work-days, gained life-
years)? 
√ √  √ √ √ 2/3 (ii-
iii) 
6. Were costs and 
consequences valued 
credibly? 
√ √  √  √ 2/4 
(ih;iv) 
7.d  Were costs and 
consequences adjusted for 
differential timing? 
N/A N/A  √ √ N/A 
8.  Was an incremental 
analysis of costs and 
consequences of alternatives 
performed? 
√ √  √ √ ×i 
9.e Was allowance made for 
uncertainty in the estimates of 
√ √ 2/3 (i 
N/A) 















N/A = not applicable. 
√ This character is used to indicate appropriate practice (rather than ‘yes’ or ‘no’ each of which can be the 
appropriate answer to specific questions). The Roman numerals indicate the question that was considered to 
be adequately fulfilled. What about the Arabic numbers, 1/3? 
a,b,c,d,e,f
 See below under individual questions 
g Based on information obtained from three papers 
h
 Yes, but based on LOS costs of unknown origin. 
i
 Based on a cost impact analysis. 
 
1. (i) Did the study examine both costs and effects of the service(s) or programme(s)? (ii) Did the 
study involve a comparison of alternatives? (iii) Was a viewpoint for the analysis stated and was 
the study placed in any particular decision-making context? 
2. (i) Were any relevant alternatives omitted? [aThis question was omitted from the evaluation 
because it is almost always possible to omit a relevant alternative e.g. composition and texture of 
ONS] (ii) Was (should) a do-nothing alternative (be) considered? 
3. (i) Was this done through a randomised, controlled clinical trial?  If so, did the trial protocol 
reflect what would happen in regular practice? (ii) Were effectiveness data collected and 
summarised through a systematic overview of clinical studies? [bThis question was omitted 
because formal systematic reviews are not generally included in primary reports of clinical 
costs and consequences? 
10.f Did the presentation and 
discussion of study results 
include all issues of concern 
to users? 
















studies] If so, were the search strategy and rules for inclusion or exclusion outlined? (iii) Were 
observational data or assumptions used to establish effectiveness?  If so, what are the potential 
biases in results? 
4. (i) Was the range wide enough for the research question at hand? [cQuestion (i) was evaluated but 
the next two were not because they were considered ambiguous or irrelevant] (ii) Did it cover all 
relevant viewpoints? (Possible viewpoints include the community or social viewpoint, and those 
of patients and third-party payers.  Other viewpoints may also be relevant depending upon the 
particular analysis). (iii) Were capital costs, as well as operating costs, included?  
5. (i) Were the sources of resource utilisation described and justified? (ii) Were any of the identified 
items omitted from measurement?  If so, does this mean that they carried no weight in the 
subsequent analysis? (iii) Were there any special circumstances (for example, joint use of 
resources) that made measurement difficult?  Were these circumstances handled appropriately? 
6. (i) Were the sources of all values clearly identified?  (Possible sources include market values, 
patient or client preferences and views, policy-makers’ views and health professionals’ 
judgements.) (ii) Were market values employed for changes involving resources gained or 
depleted? (iii) Where market values were absent (for example, volunteer labour), or market values 
did not reflect actual values (such as clinic space donated at a reduced rate), were adjustments 
made to approximate market values? (iv) Was the valuation of consequences appropriate for the 
question posed (that is, has the appropriate type or types of analysis – cost-effectiveness, cost-
utility, cost-benefit – been selected)? 
7. (i) Were costs and consequences that occur in the future ‘discounted’ to their present values? 
[dDiscounting was considered necessary only for studies with a duration of longer than one year] 
7(ii) Was any justification given for the discount rate used? 
8. (i) Were the additional (incremental) costs generated by one alternative over another compared to 















9. (i) If patient-level data on costs or consequences were available, were appropriate statistical 
analyses performed? (ii) If a sensitivity analysis was employed, was justification provided for the 
ranges of distributions of values (for key study parameters), and the form of sensitivity analysis 
used? [e A comparison of results obtained with intention to treat analysis and per protocol analysis 
was considered to be a type of sensitivity analysis, especially when the number of subjects in the 
‘per protocol’ or ‘as completed’ analysis was substantially reduced] (iii) Were the conclusions of 
the study sensitive to the uncertainty in the results, as quantified by the statistical and/or sensitivity 
analysis? [This question is not addressed by this table, but it is considered in the text] 
10. (i) Were the conclusions of the analysis based on some overall index or ratio of costs to 
consequences (for example, cost-effectiveness ratio)?  If so, was the index interpreted intelligently 
or in a mechanistic fashion? (ii) Were the results compared with those of others who have 
investigated the same question?  If so, were allowances made for potential differences in study 
methodology? (iii) Did the study discuss the generalisation of the results to other settings and 
patient/client groups? [f Any discussion relevant to alternative care settings and/or patient/client 
groups was considered to satisfy this criterion].  (iv) Did the study allude to, or take account of, 
other important factors in the choice or decision under consideration (for example, distribution of 
costs and consequences, or relevant ethical issues)? (v) Did the study discuss issues of 
implementation, such as the feasibility of adopting the ‘preferred’ programme given existing 
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identified (including one which was part of  a cost-effectiveness analysis1, and one in which 11 
the hospital component was established from the costing template2). Only two of the studies 12 
involved prospective cost-analyses3, 4. Of the 11 cohort controlled studies found in the 13 
BAPEN report5, five involved abdominal surgery4, 6-9, two orthopaedic surgery3, 10, three non-14 
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models based on previously published clinical data. One of these, which was published only 4 
recently1 and which was identified by the literature search, used a sophisticated mathematical 5 
model to examine the effect of intensive nutritional support in preventing the development of 6 
pressure ulcers in a high risk population, and to calculate the potential number of bed-days 7 
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model used information from a variety of sources, including interventional data from a meta-9 
analysis of 5 RCTs17 of subjects with a mean age of 80 years and over, with and without 10 
malnutrition according to anthropometric criteria. It also used observational data on the 11 
prevalence of malnutrition (32%; half of which was assumed to be untreated), and the risk of 12 
developing pressure ulcers (4.6%), which were assumed to extend length of hospital stay 13 
(4.31 days)18 . The model also assumed that the response of the general population of 14 
malnourished subjects in Queensland reflected that suggested by the above mentioned meta-15 
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     The second cost-effectiveness model developed by NICE16 (not identified by the literature 17 
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     Fourteen cost-analyses based on interventions exclusively in the hospital setting were 10 
identified (including one which was part of  a cost-effectiveness analysis1, and one in which 11 
the hospital component was established from the costing template2). Only two of the studies 12 
involved prospective cost-analyses3, 4. Of the 11 cohort controlled studies found in the 13 
BAPEN report5, five involved abdominal surgery4, 6-9, two orthopaedic surgery3, 10, three non-14 
surgical treatments11-13 and one mixed surgical and non-surgical14). The studies in this review 15 
were RCTs apart from four: a prospective cohort control study3; an observational study 16 
examining the impact of ONS15; a study based on an economic model with both observational 17 
and RCT data1; and the NICE cost-impact report, which was  based on a range of published 18 
clinical data and of expert opinion about current practice. In this last document, the cost of 19 
the current pathway of nutritional care in England was compared to that of a proposed 20 
pathway which incorporated the NICE clinical guidelines/quality standard2. The proposed 21 
pathway incurred extra costs, due to more screening, assessment and nutritional support, but 22 
it also produced cost savings, due to the effect of ONS in reducing healthcare utilisation. Of 23 
the three papers that were picked up from the literature search, two3, 4 were subjected to 24 
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     Two cost-effectiveness analyses were identified1, 16, both of which involved economic 3 
models based on previously published clinical data. One of these, which was published only 4 
recently1 and which was identified by the literature search, used a sophisticated mathematical 5 
model to examine the effect of intensive nutritional support in preventing the development of 6 
pressure ulcers in a high risk population, and to calculate the potential number of bed-days 7 
gained and the cost saving (2002/03 prices) in public hospitals in Queensland Australia. The 8 
model used information from a variety of sources, including interventional data from a meta-9 
analysis of 5 RCTs17 of subjects with a mean age of 80 years and over, with and without 10 
malnutrition according to anthropometric criteria. It also used observational data on the 11 
prevalence of malnutrition (32%; half of which was assumed to be untreated), and the risk of 12 
developing pressure ulcers (4.6%), which were assumed to extend length of hospital stay 13 
(4.31 days)18 . The model also assumed that the response of the general population of 14 
malnourished subjects in Queensland reflected that suggested by the above mentioned meta-15 
analysis of older people.   16 
     The second cost-effectiveness model developed by NICE16 (not identified by the literature 17 
search) calculated the extra costs required to gain a quality adjusted life year (QALY)  when 18 
a ‘don’t treat’ group of hospital inpatients  ≥ 65 years old  was compared to one managed by 19 
a pathway involving screening with the ‘Malnutrition Universal Screening Tool’ (MUST), 20 
assessment and treatment of patients identified as being ‘malnourished’ with ONS and a 21 
certain amount of enteral tube feeding. The much larger extra costs needed to support patients 22 
whose life was extended through use of ONS in hospital was taken into account. The model 23 
included the following information: results of systematic reviews with meta-analyses of 24 
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malnutrition discharged from hospital, which was assumed to be half of that of subjects from 4 
the general population according to age specific mortality statistics. A pathway involving a 5 
nurse strategy which included clinical screening and treatment was also considered.  6 
     Most studies included in this review reported clinically relevant outcomes, such as 7 
mortality, muscle strength and post-operative complications without undertaking formal cost-8 
effectiveness analyses. One RCT comparing ONS with no ONS reported that there were no 9 
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UK = United Kingdom; US = United States; CH = Switzerland; BE = Belgium; AU = Australia; DE = Germany;   2 
RCT = randomised controlled trial; ONS = oral nutritional supplement; BMI = body mass index; NICE = National Institute for Health and Care Excellence;  CEA = cost-3 
effectiveness analysis; BAPEN= British Association for Enteral and Parenteral Nutrition; ‘MUST’ = ‘Malnutrition Universal Screening Tool’; GI = gastrointestinal; BW = 4 
body weight; MNA = Mini Nutritional Assessment; TSF = triceps skinfold thickness; MAC = mid-arm circumference; NHS RD = National Health Service Research and 5 
Development; SGA = Subjective Global Assessment; Abst = abstract. SEM =Standard Error of the Mean; SD = Standard Deviation 6 
a In cost-effectiveness studies ‘cost /effectiveness measure’ represents the extra cost per unit effectiveness measure gained e.g. ‘cost/QALY’ = extra cost per Quality Adjusted 7 
Life Year gained.. 8 
b
 Number of patients randomised to intervention and control groups. 9 
c
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